Combined LAI Treatment for HIV/AIDS and Opioid Use Disorder
(CHOICE Trial)

Recruiting in Palo Alto (17 mi)

Overseen byKirsten K Langdon, Ph.D.

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase < 1

Recruiting

Sponsor: Rhode Island Hospital

No Placebo Group

Trial Summary

What is the purpose of this trial?

This is a one-year study that seeks to evaluate perspectives of combined injectable treatment for HIV and OUD. Specifically, with the development of new long-acting medications such as cabotegravir co-administered with rilpivirine (CAB/RPV) and extended-release buprenorphine (XR-B) there is a need to better understand factors that influence the delivery and uptake of this type of treatment. Therefore, this study will conduct qualitative (1:1) interviews with 32-45 key stakeholders to assess interest, knowledge, attitudes, barriers, and facilitators to integrated injectable treatment. Our team will utilize qualitative findings to inform clinical strategies to promote uptake and maintenance of long-acting injectable medications for HIV and OUD.

Research Team

Kirsten K Langdon, Ph.D.

Principal Investigator

Rhode Island Hospital

Eligibility Criteria

This trial is for individuals aged 18-65 with HIV and opioid use disorder (OUD), who can communicate in English. They must have a confirmed HIV diagnosis and meet the criteria for OUD. Participants from RIDOC should expect to be released within 6 months. Pregnant or breastfeeding individuals, or those planning pregnancy or treatment for Hepatitis B/C during the study, cannot join.

Inclusion Criteria

Current diagnosis of OUD according to DSM-5

Able to understand and speak English and to provide written and verbal informed consent

I have been diagnosed with HIV.

See 2 more

Exclusion Criteria

Currently pregnant, breastfeeding, planning to become pregnant or breastfeed during the study period

I have Hepatitis B or plan to treat Hepatitis C during the study.

Treatment Details

Interventions

Combined Injectable Treatment for HIV and OUD (Other)

Trial OverviewThe study is testing a combined long-acting injectable treatment regimen: Cabenuva (cabotegravir with rilpivirine) for HIV and Sublocade (extended-release buprenorphine) for OUD. It involves interviews with stakeholders to understand factors affecting this treatment's delivery and acceptance over one year.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Preliminary Test of Combined LAI TreatmentExperimental Treatment1 Intervention

The combined injectable treatment includes a dual-administration of rilpivirine (CAB/RPV) "cabenuva" for HIV and extended-release buprenorphine (XR-B) "sublocade" for OUD.